Antiandrogenic effect of spirolactones: mechanism of action.
about
The interaction of canrenone with oestrogen and progesterone receptors in human uterine cytosol.Testotoxicosis. An unusual presentation and novel gene mutation.30 Years of the Mineralocorticoid Receptor: Mineralocorticoid receptor antagonists: 60 years of research and development.Bicalutamide and third-generation aromatase inhibitors in testotoxicosisInterfering with mineralocorticoid receptor activation: the past, present, and futureHirsutism and the effectiveness of spironolactone in its management.Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI.Eplerenone--a novel selective aldosterone blocker.Displacement of cortisol from human heart by acute administration of a mineralocorticoid receptor antagonist.Polycystic ovary syndrome: chemical pharmacotherapy.Role of the selective aldosterone receptor blockers in arterial hypertension.Novel antihypertensive agents.Testotoxicosis: gonadotrophin-independent male sexual precocity.Does eplerenone have a future in the management of hypertension in Europe?Lack of effect of spironolactone on hair shaft diameter in hirsute femalesThe management of patients with polycystic ovary syndrome.Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.Adverse effects of common medications on male fertility.Imatinib and spironolactone suppress hepcidin expression.Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.Low serum testosterone is associated with adverse outcome in men with cirrhosis independent of the model for end-stage liver disease score.High circulating estrone and low testosterone correlate with adverse clinical outcomes in men with advanced liver disease.Gender-Affirming Pharmacological Interventions for Youth With Gender Dysphoria: When Treatment Guidelines Are Not Enough.Sexual Reassignment Fails to Prevent Kennedy's Disease.Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies.Drug points: Hair: wanted and unwanted.Treatment of hyperandrogenism in womenAndrogens and Therapeutic Aspects of Antiandrogens in WomenLack of endocrine systemic side effects after topical application of spironolactone in manRationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease
P2860
Q24542420-0949A160-9089-4928-8430-21A4E6488524Q30464399-CE68CD7A-1BB6-4083-B118-9BB89591C6CDQ33846431-334FB637-BFAB-4BD9-A9CE-C234F9DC0FEBQ33896972-8BFD9DA4-7471-4B4B-BB3E-8550685CAD2FQ34019947-A57FE03D-F43A-4D7A-A2C4-1DF8CDC8E4BBQ34338540-2A40E952-9189-4B57-859D-4AB46B745980Q34521960-7AFBD93F-1FBA-48ED-B880-9BA43C8188D6Q34874363-EDCA5F52-BEAA-41B2-B19B-726B279B3AFDQ35358929-FA73E0D2-0427-4B3B-AD67-9D273D901FE8Q35639510-1414903D-B7DA-4D0D-A79F-036B92425D57Q35770241-8B2E91A1-4793-4D5B-A76D-53A3C17C16F5Q35842537-4D6A9DA3-43C2-4988-A532-C3849C48C6A9Q36127629-B65535F2-FA84-4543-BA30-5DB39E92FE7CQ36568473-662015B4-92D1-4DB6-A437-BC77BDB71806Q36723408-F222CEA9-C550-450D-B6D0-19EA179A0C0BQ38229280-56775525-BA00-4D5E-89E1-63253CBE8E0BQ38533385-E7B0E077-7F3C-4E90-95E7-0CA4D4113833Q38534996-DDEC5E91-BA60-4C94-AB67-3177B84F3E17Q38708587-86EBD5C9-6B66-4973-9EFF-1A75ED3D18D3Q38850114-452AA5A4-FD5F-4D38-A82C-DEF8EB77DF6FQ39473080-6760FD49-8A90-43A0-B7A6-AB746A9AC075Q39902366-C6CE1C54-A201-4791-BB95-0D8C34287C78Q47681246-6D2A864F-A0FA-4D7B-9AA6-775263355430Q47944992-1AE6F99D-CF41-4BFD-841A-A9B51714B86EQ51293660-F5C2D6FB-2375-4B72-A102-CA9517B11DF0Q55481016-EC636B66-9CD8-4E17-996D-C858BD9C3692Q55892518-5AE768AF-15A7-4969-9335-FCFC8038C07CQ55954238-06580E8D-3C1E-4E99-9F2E-B484914884AFQ56429451-BAC2B4C9-DD8E-4A6E-B3D4-31AB037F71B2Q57911462-BC289A5D-ED36-42C0-AED2-06AA2B264883
P2860
Antiandrogenic effect of spirolactones: mechanism of action.
description
1975 nî lūn-bûn
@nan
1975 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1975 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1975年の論文
@ja
1975年論文
@yue
1975年論文
@zh-hant
1975年論文
@zh-hk
1975年論文
@zh-mo
1975年論文
@zh-tw
1975年论文
@wuu
name
Antiandrogenic effect of spirolactones: mechanism of action.
@ast
Antiandrogenic effect of spirolactones: mechanism of action.
@en
Antiandrogenic effect of spirolactones: mechanism of action.
@nl
type
label
Antiandrogenic effect of spirolactones: mechanism of action.
@ast
Antiandrogenic effect of spirolactones: mechanism of action.
@en
Antiandrogenic effect of spirolactones: mechanism of action.
@nl
prefLabel
Antiandrogenic effect of spirolactones: mechanism of action.
@ast
Antiandrogenic effect of spirolactones: mechanism of action.
@en
Antiandrogenic effect of spirolactones: mechanism of action.
@nl
P2093
P356
P1433
P1476
Antiandrogenic effect of spirolactones: mechanism of action.
@en
P2093
P356
10.1210/ENDO-97-1-52
P407
P577
1975-07-01T00:00:00Z